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Abstract: Pathogenic processes underlying Alzheimer’s disease (AD) affect synaptic function from
initial asymptomatic stages, long time before the onset of cognitive decline and neurodegeneration.
Therefore, reliable biomarkers enabling early AD diagnosis and prognosis are needed to maximize
the time window for therapeutic interventions. MicroRNAs (miRNAs) have recently emerged as
promising cost-effective and non-invasive biomarkers for AD, since they can be readily detected
in different biofluids, including cerebrospinal fluid (CSF) and blood. Moreover, a growing body
of evidence indicates that miRNAs regulate synaptic homeostasis and plasticity processes, sug-
gesting that they may be involved in early synaptic dysfunction during AD. Here, we review the
current literature supporting a role of miRNAs during early synaptic deficits in AD, including recent
studies evaluating their potential as AD biomarkers. Besides targeting genes related to Aβ and
tau metabolism, several miRNAs also regulate synaptic-related proteins and transcription factors
implicated in early synaptic deficits during AD. Furthermore, individual miRNAs and molecular
signatures have been found to distinguish between prodromal AD and healthy controls. Overall,
these studies highlight the relevance of considering synaptic-related miRNAs as potential biomarkers
of early AD stages. However, further validation studies in large cohorts, including longitudinal
studies, as well as implementation of standardized protocols, are needed to establish miRNA-based
biomarkers as reliable diagnostic and prognostic tools.
Keywords: miRNAs; synaptic dysfunction; Alzheimer’s disease; biomarkers
1. Introduction
Alzheimer’s disease (AD) is a progressive and irreversible brain disorder and the
most frequent form of dementia among the elderly, reaching nearly 70% of cases [1,2].
Although the development of the disease is variable between patients, three phases can
be distinguished as part of a continuous process of degeneration (Figure 1): (1) The
preclinical phase, usually lasting more than 10 years, characterized by early changes in
biomarkers in the absence of clinical symptoms; (2) the prodromal phase comprising the
earliest symptomatic stage of the disease when cognitive decline starts to be evident while
biomarker levels do not reach the cutoff criteria for diagnosing dementia [3], and (3) a
dementia stage in which the pathology and symptomatology is fully developed [4]. The
duration of each phase is not constant but rather depends on the age of onset, gender, and
genetic risk factors [5].
The development of these stages is related to the spread of pathological changes across
different brain regions. AD pathological hallmarks, comprising accumulation of amyloid-β
peptide (Aβ) aggregates forming extracellular plaques, and hyperphosphorylated species
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of tau microtubule-associated protein, forming intraneuronal neurofibrillary tangles (NFTs)
are known to follow an anatomical-temporal pattern starting in the temporal lobe and
spreading to neocortical areas at later stages [6,7]. Although amyloid plaques are irreg-
ularly distributed in the brain, and their accumulation does not correlate with cognitive
impairment [8], NFTs tau pathology progress pattern tends to be mostly maintained be-
tween patients [6]. Due to the stability of this pattern, NFTs pathology is the base of the
most used pathological classification of the disease, established by Braak and Braak three
decades ago [6]. The first two stages (I-II) could be associated with a preclinical phase of
the disease, where tau pathology is mainly focused on the entorhinal cortex with subtle
hippocampus affection [7,9] accompanied by synaptic function alteration. In stages III-IV
the pathology affects the subcortical limbic region and clinically might correspond to the
prodromal phase. Finally, during the last stages (V-VI), the pathology spreads to most
neocortical areas [6,7] with observable extensive neuronal death, corresponding with AD
dementia [6,9]. Increasing evidence in AD experimental models suggest that this progres-





Figure 1. Main stages and features of Alzheimer’s disease. Pathological changes and cognitive symptoms are represented
as blue and brown lines, respectively. Pathological hallmarks currently used as biomarkers (Aβ and tau) are shown in blue
rectangles, while key global pathological changes are indicated with arrows. Cognitive symptoms are summarized as MCI
(mild cognitive impairment) and dementia stages. miRNA-based signatures for potential diagnosis of MCI and AD stages
are indicated as references.
Despite the huge amount of work done in the field during the last decades, and
the significant advances achieved, our knowledge of the mechanisms underlying this
multifactorial complex disease is still limited. This fact added to the lack of accessible and
reliable methods for detecting preclinical phases has probably led to the failure of potential
therapies so far [11]. In this regard, both preclinical and prodromal stages represent a
potential therapeutic window where novel pharmacological and non-pharmacological
therapies are more likely to delay the progression of the disease and improve the lives of
patients. Therefore, it is urgent to improve the tools currently available to achieve a reliable
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and earlier detection of AD, ideally during initial phases characterized by alteration of
synaptic function [12].
In this article, we will review the literature supporting the role of miRNAs in synaptic
dysfunction, with special focus on their potential as early biomarkers for AD, both as
diagnostic and prognostic tools.
2. Synaptic Function and Synaptic Alteration in AD
Changes in synapses’ structure and function involve gene regulatory networks control-
ling spine development, maturation, and maintenance. Interestingly, mutations in genes
encoding synaptic proteins, and mutations in genes related to Aβ metabolism/clearance
have been related to AD risk [13]. An increasing amount of evidence indicates that cognitive
decline observed in the early stages of neurodegenerative diseases such as AD is a con-
sequence of synaptic alterations that occurs before neurodegeneration takes place [14,15].
Since aberrant changes in dendritic spine morphology and density linked to altered number
and function of neurotransmitter receptors contribute to synaptic failure in AD [15], better
knowledge of both physiology and pathology of synapses is necessary to understand the
mechanisms underlying AD pathology.
Synapses are dynamic structures whose correct function requires highly specialized
molecular machinery at both pre- and post-synaptic terminals. Whereas pre-synaptic
terminals are structurally similar in inhibitory and excitatory synapses, post-synaptic com-
partments differ in their organization [16]. Inhibitory synapses are typically located at the
dendritic shaft or even at the neuronal soma where gephyrin anchors GABA receptors in
the membrane. On the contrary, excitatory synapses containing glutamate receptors mostly
rely on the dendritic spine structure, specialized protrusions of diverse sizes and shapes
that allow a greater concentration of synapses in a compact area of the post-synaptic termi-
nal [17]. Formed by a complex organization of scaffold proteins (including homer, shank,
and PSD-95 protein families), the post-synaptic density (PSD) supports the structure of the
post-synapse, anchoring ionotropic glutamate N-methyl-D-aspartate receptors (NMDAR)
and synaptic α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPAR)
as well as metabotropic glutamate receptors (mGluRs) in the cell surface together with a
large number of signaling molecules and actin filaments [18].
Synapses are able to modify their structure and function upon neural activity, adapting
the strength or efficacy of synaptic transmission to different contexts in a process known
as synaptic plasticity [19]. Between several synaptic plasticity mechanisms that can occur
in pre- and post-synaptic compartments, the most widely studied and understood are
long-term potentiation (LTP) and long-term depression (LTD) processes in which both
NMDAR and AMPAR could be involved. Initial Ca2+ influx through post-synaptic NM-
DAR regulates the recruitment or removal of synaptic AMPAR, reinforcing or weakening
synaptic transmission, respectively, processes thought to underlie learning and memory
functions [20,21].
The PSD-95 family is the most abundant post-synaptic scaffolding protein within
the PSD containing three protein-protein interaction motifs (PDZ domains) that facilitate
signal coupling by bringing together cytoplasmic signaling molecules such as kinases and
phosphatases close to their substrate, controlling receptor assembling at synapses [18,22].
Different members of the PSD-95 family mediate AMPAR targeting to mature synapses
supporting synaptic transmission and are also able to interact with transmembrane AMPAR
regulatory proteins (TARP) stabilizing new synaptic AMPAR at the synapse [23]. Moreover,
PSD-95 connects pre- and post-synaptic elements through the interaction with cell-adhesion
molecules (CAMs) such as, neuroligins, neurexins, ephrins, or cadherins [24,25]. CAMs, at
the same time, can be linked to F-actin cytoskeleton, giving a stable but flexible structure to
the dendritic spines that underlies synaptic communication.
As expected, synaptic dysfunction observed in early AD patients is associated with
extensive loss of synaptic markers [26,27] and a relationship between dysregulation of
synaptic proteins and early cognitive dysfunction has been remarked [27,28]. Cognitive
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function evaluated by tests such as the Mini-Mental State Exam (MMSE) or the delayed
word list recall tests that evaluate hippocampus-dependent tasks exhibit a positive correla-
tion with the number of synapses in brain related areas as the hippocampus and frontal
cortex of early AD patients [14,29].
Interestingly, synaptic density constitutes a better correlation with clinical symptoms
than classical AD histopathological markers such as amyloid plaques and NFT [14,26,29,30].
In this regard, solid evidence indicates that oligomeric forms of Aβ (oAβ), instead of amyloid
plaques, contribute to synaptic alterations and correlate with synaptic loss [12,31–33]. In the
same line, it has been described that Aβ aggregation is enriched at synapses even before the
formation of amyloid plaques or tau NFT [34].
Accordingly, oAβ are thought to initiate the pathological events described as the
amyloid cascade hypothesis [35], according to which changes in Aβ metabolism result
in its oligomerization that initially triggers disruption and loss of synaptic connections
follow by inflammatory response involving microglial and astrocytic activation, alteration
of calcium homeostasis and oxidative stress resulting in neurodegeneration. Indeed, oAβ
were shown to alter pre-synaptic functions such as axonal transport, synaptic vesicles traf-
ficking and recycling, and neurotransmitter release [36]. Moreover, evidence indicate that
oAβ also affect post-synaptic function and are especially toxic to glutamatergic synapses.
Dysregulation of glutamatergic transmission is the main described mechanism by which
oAβ could alter spines shape and number [33,37–40] leading to synaptic failure [37]. For
instance, the cascade triggered by oAβ affect the regulation of downstream kinases and
phosphatases that increase NMDAR and AMPAR internalization [28,37,40], creating an
imbalance between LTP and LTD. While these structural and functional alterations have
been shown to contribute to cognitive dysfunction present in AD patients [41], several
studies have also linked AMPAR decrease in the cell surface with synaptic alterations
in AD experimental models, including primary neuronal cultures and transgenic mice
models [28,42] in which, interestingly, a correlation also exists with learning and memory
deficits [27,28]. Moreover, loss of synapses in the CA1 of transgenic mice models of AD are
consistent with the synapse loss described in AD [15].
Furthermore, oAβ would facilitate tau phosphorylation, which in turn decreases its
affinity for microtubules and facilitates its aggregation and NFTs formation contributing
to signaling deficiency and neurodegeneration [43]. On the other hand, besides the well-
known role of tau in microtubule assembly, studies in transgenic mice highlighted a
dendritic role for tau during synaptic pathology [44–46]. During pathological processes,
tau is able to bind to scaffolding proteins and glutamate receptors at the PSD affecting
synaptic function by altering LTP-LTD balance [32]. In addition, tau has been shown to
be necessary for Src-family tyrosine kinase Fyn recruitment to post-synaptic NMDAR
complexes in a mechanism that mediates Aβ excitotoxicity [46]. Thus, both Aβ and tau
constitute key pathogenic players in early neurodegenerative processes linked to AD [32],
and they are thought to interact locally at synapses leading to synaptic failure and cognitive
impairment [30,47,48].
3. miRNAs as Mediators of Synaptic Dysfunction in AD
Increasing evidence indicates that the alteration of protein functionality in the synapse
could be involved in early synaptic alterations in AD [26,27]. Given the regulatory role of
miRNAs, those miRNAs targeting synaptic-related proteins may be an important mecha-
nism underlying the synaptic dysfunction present in early stages of the disease [49]. Thus,
alterations in the levels of specific miRNAs could be important in the development of
synaptic pathology that leads to neurodegeneration in AD by modifying the synaptic
structure and function that underlie synaptic plasticity. In addition, miRNAs are capable
of regulating the mechanisms of toxicity mediated by central factors of the pathology
such as tau and Aβ. Moreover; miRNAs can be enveloped in membranous vesicles that
can be released to the peripheral circulation in the form of extracellular vesicles such as
exosomes, favoring miRNAs conservation [50]. In this context, it is reasonable to think that
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the possibility of detecting alteration in the levels of specific miRNAs during pathology
constitutes a valuable tool for AD detection. Indeed, these facts have opened a very prolific
field with an increasing number of candidates to be used as biomarkers for AD, among
which, synaptic-related miRNAs seem the most promising candidates as biomarkers for
the detection of early stages of AD since synaptic dysfunction precedes neurodegeneration
and the clinical symptoms.
3.1. Synaptic Role of miRNAs
miRNAs are the most studied small noncoding RNAs (ncRNAs), a class of functional
RNA molecules of approximately 22 nucleotides (nt) of length, lacking protein-coding
properties. Over 2600 human mature miRNAs have been annotated so far (miRBase.org)
and conserved miRNA-binding sites have been detected in more than 60 percent of protein-
coding genes, suggesting a wide presence of miRNA-mediated gene expression regula-
tion [51].
miRNAs post-transcriptionally regulate gene expression by associating with Arg-
onaute (Ago) proteins to form the RNA-induced silencing complex (RISC). Binding by
partial sequence complementarity usually to the 3-untranslated region (3′-UTR) of target
messenger RNAs (mRNAs), a single miRNA could repress mRNA translation of hundreds
of different targets [51,52] constituting a fine regulatory mechanism of protein expression.
Although a repression of translation is the main mechanism of miRNAs regulation, other
mechanisms including an increase in translation, have also been reported [53].
Many studies have shown the presence of specific miRNAs (including miR-9, miR-15b,
miR-16, miR-135a/b miR-204, and miR-221) in axons and have related them to axon growth
and branching [54–56]. Other studies have found highly expressed miRNAs (such as
miR-9, miR-26a, miR-125b, miR-128, miR-132, miR-134, miR-138, miR-181a, or miR-218)
within neuronal dendrites in diverse brain areas, including the hippocampus [55,57–59].
Importantly, not only mature miRNAs, but also precursor-miRNAs (pre-miRNA) and the
RNAse III Dicer needed for miRNAs maturation, have been found within dendrites [58,60].
The enrichment of specific miRNAs in axons and dendrites indicates a potential
role for miRNAs locally regulating protein levels, thus synaptic structure and function.
In this regard, an elegant study by Erin M. Schuman and colleagues has demonstrated
that synaptic activity can increase the processing of pre-miRNAs locally in dendrites. In
particular, local maturation of miR-181a and subsequent decrease in its target CaMKIIα has
been described [61]. Local regulation of Ca2+ signaling cascades related to learning and
memory processes following neuronal activity through this key kinase, would constitute a
fast local mechanism of synaptic function regulation by miRNAs [61].
Of particular interest, several transcription factors and co-activators such as the cyclic
adenosine monophosphate (cAMP) response element-binding protein (CREB), CREB- regu-
lated transcription coactivator-1 (CRTC1), and nuclear factor-kappa-light-chain-enhancer
of activated B cells (NF-κB), have been related to AD. Interestingly, some of these tran-
scriptional regulators are synaptonuclear factors implicated in regulating transcriptional
programs related to synaptic function, often in an activity-dependent manner and through
integration of signals mediated by CREB [62]. This transcription factor plays an essential
role in activating transcriptional programs underlying synaptic plasticity [19]. Thereby,
miRNAs binding to transcription factors would be able to regulate synaptic function. In
this regard, Gerhard M. Schratt and colleagues have reported that CREB and myocyte en-
hancing factor 2 (MEF2) (a transcription factor that negatively regulates excitatory synapses’
number) regulate the expression of miR-212/132 family where miR-132 and miR-134 are
included. Conversely, these miRNAs and other members of the family regulate CREB,
SIRT, and the methyl CpG-binding protein 2 (MeCP2) expressions that can in turn regulate
BDNF levels, triggering the induction of miR-212/132 expression. Indeed, miR-132 can
bind directly to BDFN and regulate its expression. This complex regulatory loop constitutes
a mechanism by which miRNAs can control their own levels in response to neural activity
changes [63].
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The specific case of miR-134, a brain specific miRNA and activity regulated member of
this family, has been largely studied by Schratt et al. [64,65]. They have observed that miR-
134 can be transported to dendrites as a mature miRNA, but it also exists as pre-miRNA in
the synapto-dendritic compartment. Locally, miR-134 can mature when needed and can
negatively regulate dendritic spines size targeting LIM domain kinase 1 (Limk1), involved
in spine maturation. Interestingly, following synaptic activity, the repression that miR-134
exert over Limk1 translation is released, and dendritogenesis is promoted [64,65]. On the
other hand, miR-134 can also facilitate homeostatic synaptic depression in response to
chronic activity, targeting the local translational repressor Pumilio-2 [66]. Recently, miR-134
localization in dendrites has been supported using atomic force microscopy showing a
negative correlation between the amount of miRNA and the maturity and function of
synapses [49]. Other members of the family, miR-132 and miR-138, were also linked to
synaptic formation and function [63].
Interestingly, miR-29a/b are known to bind to Arpc3 subunit of the ARP2/3 complex,
involved in regulation of actin filament branching and dendritic spine morphogenesis [67],
whereas miR-191 is known to target tropomodulin-2, a neuron-specific regulator of actin
dynamics that decrease in response to increased miR-191 expression following NMDAR
activity during LTD [68]. Similarly, miR-9 has been reported to target transcriptional
repressor REST, thereby, acting as a mediator in mRNA translation activation, necessary
for functions such as dendritic growth [69].
Since glutamatergic transmission plays a key role in synaptic function and plasticity
processes, the study of miRNAs targeting excitatory synapses and specially glutamate
receptors has caught special attention. For instance, the brain-enriched miR-9-3p above
mentioned, targets SAP97 (a member of PSD-95-like membrane associated guanylate
kinases-PSD-MAGUKs-) that binds to mRNA coding for the GluA1 AMPAR subunit, thus,
modulating AMPAR trafficking [70]. Moreover, miR-92, miR-137, and miR-501 are able to
selectively regulate GluA1 trafficking, so that their overexpression in vitro reduces AMPAR
insertion in cell surface during homeostatic scaling [71–73]. In addition, other studies
have indicated the direct regulation of GluA2 subunit by miR-124 [74], miR-218 [75] and
miR-186 [76] in an activity-dependent manner. Of interest, Olde Loohuis and colleagues
have reported that in addition to the regulation that miR-137 exerts on AMPAR-mediated
synaptic transmission and the turnover between silent and active synapse, an activity
dependent mechanism is in turn regulating miR-137 levels. Upregulation of miR-137 levels
was observed following metabotropic glutamate receptor 5 (mGluR5) activation, leading to
a negative feedback mechanism controlling mGluR5-dependent synaptic plasticity [73].
miRNAs regulating NMDAR expression have also been reported, for instance, miR-
139-5p [77] and miR-125b [78] have been involved in synaptic plasticity regulation by
binding to mRNA coding for NR2A subunit while miR-539 and miR-34a regulate NR2B
subunit of NMDAR [79,80]. Moreover, indirect regulation of NMDAR through miR-128
binding to STIM2 (stromal interaction molecule 2) has also been suggested as a miRNA-
mediated mechanism of synaptic plasticity modulation [81].
Regarding receptors regulation, the modulation of proteins related to receptor traf-
ficking and function is also of great interest. For instance, miR-181c is predicted to target
neuronal pentraxin 1 (NPTX1) and neuronal pentraxin receptor (NPTXR) while miR-210
has been shown to regulate the levels of both proteins [82] implicated in the modulation
of glutamatergic transmission through modulation of AMPAR recruitment and cluster-
ing [83]. Interestingly, whereas miR-210 at the post-synaptic terminals is involved in the
regulation of receptor trafficking and synaptic plasticity, at the pre-synaptic terminal, it has
been shown to target SNAP25, participating in neurotransmitter release [84]. Regarding
pre-synaptic function, miR-137 over-expression has been reported to alter synaptic vesicle
docking accompanied by a decrease in active zone size and in synaptic vesicles number
in hippocampal cultures, human-induced neurons, and in vivo experiments performed
in mice [85]. Moreover, miR-485 has been associated with altered functional synapses
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number, spine maturation, PSD-95 clustering, and surface GluA2 expression by targeting
the synaptic vesicle glycoprotein 2A (SV2A) involved in neurotransmitters release [86].
Given the central role of glutamatergic transmission in synaptic plasticity processes,
the study of miRNAs targeting excitatory synapses, and especially glutamate receptors,
has particularly grown during the last years. However, Katharine R. Smith and colleagues’
recent work has put the focus on GABAA receptor regulation by miR-376. In this study,
a mechanism by which miR-376 locally inhibit GABRA1 and GABRG2 translation in den-
drites has been reported [87]. In this context, dendrite local de novo synthesis of synaptic
GABAAR has been described, constituting a mechanism of long-term surface GABAAR
clustering conservation during iLTP expression. Additionally, they described another level
of regulation of this receptor, by which miR-376 is repressed through a calcineurin-NFAT-
HDAC signaling pathway following NMDA-induced inhibitory long-term potentiation
(iLTP), relieving miRNA-inhibition on GABAAR subunits translation.
Data reviewed in this section (summarized in Table 1 and Figure 2) strongly support
an essential role of miRNAs in synaptic plasticity modulation and consequently suggested
their implication also in synaptic dysfunction related to neurodegenerative diseases. Cer-
tainly, understanding how specific miRNAs regulate synaptic function at different levels is
essential to complete the full landscape of mechanisms underlying AD pathology, especially
regarding synaptic failure present in the early stages of the disease.
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NTs: Neurotransmitters, GluRs: Glutamate receptors.
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Table 1. Key synaptic-related targets and reported miRNAs regulating them.
Key Targets Relevant Function Related-miRNAs Ref. Related miRNAs
BACE1 TNF-α, ephrin-A2, and APPcleavage miR-9, miR-107, miR-29a/b [88–92]
SIRT1
Acetylation of substrates







GSK3B Phosphorylation of keyrelated targets including tau miR-26a [95]
MEF2D Transcription factor involvedin structural plasticity miR-92 [96]
CREB1 Transcription factor involvedin synaptic plasticity miR-132, miR-134 [63]








IGF1 Growth factor involved insynapse maturation miR-26b, miR-206 [97]
BDNF Neurotrophic factor involvedin synaptic plasticity miR-132, miR-206 [98]
MME (NEP) Neurite outgrowth miR-26b [99]
EFNA3 (Ephrin-A3) Axon guidance miR-210 [82]
DCX Axon assembly and branching miR-29a [100]
ARPP21 Dendritic branching miR-128 [101]
p250GAP Actin reorganization indendritic spines. miR-132 [102]
LIMK1 Actin cytoskeletonorganization miR-134 [64,65]
PUM2 Actin cytoskeletonorganization miR-134 [66]
TMOD2 Actin filaments organization miR-191 [68]
DPYSL2 (CRMP-2) Axon guidance miR-181c [103]
SNAP25 Vesicle trafficking miR-210 [84]
SV2A Neurotransmitter release miR-485 [86]
SYN2 Neurotransmitter release miR-125b, miR-181 [104]






ARPC3 Negatively regulates synapticscaling miR-29a/b [67]
MAP2 Microtubules assembly miR-26a [50]
MAP1B Microtubules stabilization miR-9, miR-146a [54,107]
DLG4 (PSD-95) Scaffold protein miR-125a [108]
NLGN1 AMPAR clustering, synaptictransmission miR-146a [106]
CAMK2A
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Table 1. Cont.






GRIA1 Synaptic transmission miR-92, miR-137, miR-501,miR-34a [71–73,109]
GRIA2 Synaptic transmission miR-181a [110]
GRIN2A Synaptic transmission miR-125b [77,78]
GRIN2B Synaptic transmission miR-34a [80,109]
Key synaptic-related targets and their functions are indicated. miRNAs targeting them that will be further discussed as potential MCI-AD
biomarkers (Table 2) are included.
3.2. miRNAs and Synaptic Dysfunction in AD
A large number of miRNAs have been shown to be dysregulated during AD progres-
sion [57,111] and in AD experimental models [89] expanding the role of miRNAs from
physiology to pathology. Considering the central role that synaptic dysfunction plays in AD
onset [30,47] the study of miRNAs particularly regulating synaptic function/dysfunction
is of special interest and highlighting them constitutes the aim of this review.
Several of the miRNAs mentioned above, known to regulate synaptic proteins, have
been suggested as important mediators of AD pathological processes (Table 1). For instance,
miR-34a has been proposed as a potential contributor to AD pathology since its increased
expression has been observed in APP/PS1 transgenic mice prior to Aβ increase, deposition
into plaques, and cognitive deficits (appearing later in this model). In contrast, synaptic
plasticity was shown to be enhanced in miR-34a-KO/APP/PS1 mice [109]. Besides multiple
synaptic targets already described for this miRNA, including AMPAR and NMDAR,
overexpression of miR-34a has been associated with a consistent reduction of sirtuin1
(SIRT1) [80]. Interestingly, other miRNAs, including miR-9 and miR-181c, have also been
proposed to target SIRT1 [93] constituting interesting candidates of synaptic regulation in
the context of AD pathology. Whereas miR-34a overexpression has also been reported to
block tau synthesis by binding directly to the 3′-UTR of human tau mRNA [112], another
member of the same family, miR-34c, has been reported to be upregulated in a transgenic
AD model and in hippocampal neurons exposed to Aβ. Aβ toxicity was able to alter
synaptic vesicle exocytosis through a miR-34c-mediated reduction of VAMP2, a protein
component of the SNARE complex. These changes were associated with synaptic failure
and learning and memory deficits, recovered after miR-34c increase blockade [105].
miR-134-5p, a well-studied brain-specific miRNA in synaptic function, has been
reported to be upregulated after hippocampal Aβ treatment in rats. Interestingly, these
results were linked to miR-134-mediated post-transcriptional regulation of CREB and
BDNF since knockdown of miR-134-5p abolished CREB and BDNF miR-134-mediated
decrease and rescues Aβ induced synaptic deficits [113]. In this way, miR-134-5p could
be involved in a main molecular mechanism underlying synaptic plasticity alterations
associated to AD.
In addition, miR-206 increased in both Tg2576 mice, and AD brain has also been
shown to regulate memory function in AD mice models by targeting BDNF [98]. miR-
206 is also able to regulate insulin like growth factor 1 (IGF1) [114]; likewise, miR-26b
was associated with an increase in Aβ production through inhibition of IGF1 translation
in vitro [97] regulate neprilysin (NEP), a type II transmembrane glycoprotein found on the
pre-synaptic membrane and which downregulation has been linked to Aβ increased levels
in mice AD model [99].
Related to AMPAR, different subunits have been validated as targets for several
miRNAs in vitro and linked to cognitive deficits in experimental rodent models of AD.
This redundant targeting of different glutamate receptor subunits suggests a complex
miRNA-mediated post-transcriptional regulation of AMPAR trafficking during homeostatic
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scaling and subsequent role in synaptic plasticity alterations present in AD. For instance,
the downregulation of miR-181a in 3xTg-AD mice rescued memory impairment through
restoration of GluA2 levels [110]. By regulating GluA2 transcripts, miR-181a participate in
Aβ-induced synaptic alterations while in the hippocampus it has been shown to regulate
soluble tau levels, constituting a negative regulator of synaptic plasticity [110]. Furthermore,
miR-30b, miR-186-5p, and miR-218 have also been reported to bind Gria2 3′-UTR and
their overexpression have been associated with a decrease in GluA2 levels regulating
synaptic function and cognitive decline in AD experimental models [76,115]. Other miRNA
targeting GluA2, miR-124, has been reported to be strongly increased in the hippocampus
of AD patients and also in AD mice model (Tg2576) accompanied by deficits in synaptic
transmission, plasticity, and memory impairment [116]. Mechanisms underlying these
synaptic deficits were further studied in vitro using hippocampal neurons, where oAβ
treatment produce a miR-124-mediated decrease of PTPN1 (protein tyrosine phosphatase
non-receptor type 1), impairing GluA2 membrane insertion [116]. Moreover, studies
in P301S mice indicate that miR-124/PTPN1 alterations could also be modulating tau
phosphorylation state through kinase/phosphatase activity imbalance [112].
Taken together, these studies showed that levels of miRNAs regulating glutamate
receptors and synaptic-related proteins are altered in AD patients and mouse models,
suggesting that they may play key pathological roles, besides informing about early
synaptic deficits during the disease progression.
3.3. Role of miRNAs in Aβ/Tau Mediated Synaptic Dysfunction and Neuroinflammation
An increasing amount of studies in the area have already provided evidence of
miRNAs dysregulated in AD, which are implicated in regulating key genes involved in the
disease onset, such as PSEN1, APP, or BACE1 [111,117].
Studies using experimental models of AD have allowed the identification of miRNAs
directly linked to tau neuropathology in AD. Regulating tau phosphorylation, specific
miRNAs can modulate tau affinity for microtubule, maintenance of microtubule network,
and tau aggregation/deposition in NFTs [43,118,119]. For instance, miR-125b and miR-138,
both frequently upregulated in AD, have been shown to increase tau hyperphosphorylation
and aggregation in neuronal cultures [120] and to impair associative learning in fear condi-
tioning test in mice model of AD [121]. Moreover, miR-132, consistently decreased in AD
studies [57,122], has also been associated with tau phosphorylation state regulation [111].
Increased tau hyperphosphorylation and aggregation was observed in 3xTg-AD mice
expressing lower levels of miR-132 accompanied by long-term memory deficits [123].
Regarding Aβ metabolism, several miRNAs including miR-9, miR-29, miR-107, miR-
124, miR-135b, miR-188, and miR-338 have been suggested to regulate β-site APP cleaving
enzyme 1 (BACE1) levels [88–92], a central enzyme in Aβ generation. One example is miR-
29a/b/c cluster, known to be decreased in AD brain [88], which correlates with increased
BACE levels. Interestingly, miR-29a/b overexpression in AD SAMP8 mice model has been
related to BACE1 and Aβ decrease, accompanied by learning and memory recovery [124].
While miR-188-3p overexpression in transgenic AD mice reduces Aβ levels through BACE1
translation inhibition [125], an association with dendritic spines alteration and synaptic
transmission deficiency by regulation of Neuropilin-2 (Nrp-2) was also reported [126]. This
way, miR-188-3p would be able to modulate the expression of glutamate receptors [125].
Furthermore, miRNAs targeting directly APP have also been described supporting the
role of miRNAs in AD pathogenesis. Specifically, miR-101 levels downregulation observed
in AD brain [88] is consistent with in vitro studies where inhibition of miR-101 increase
APP levels [127]. Moreover, miR-16 and miR-147 have also been described to target APP in
experimental models of AD pathology [128–130]. Interestingly, miR-16 expression has also
been related to tau phosphorylation in primary cortical neurons [131].
Moreover, several miRNAs have been suggested to regulate metalloproteinase ADAM10
levels, including miR-23a, miR-34a, miR-107, and miR-451 [80,132,133]. Since APP is
one of the well-known substrates of ADAM10, these miRNAs would be involved in Aβ
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metabolism. Additionally, other substrates with potential synaptic effect including cell ad-
hesion molecules such as Neuroligin-1, N-Cadherin or NrCAM, have also been established
for ADAM10 [134] relating these miRNAs to synaptic deficits linked to AD.
Otherwise, it is known that reactive astrocytes and inflammatory microglia are part of
the pathological AD environment, although outside the scope of this review, it is interesting
to point out that both cell populations produce and secrete extracellular vesicles (EVs)
that are able to fuse with target cells to which they transfer their content (containing
protein, lipids, and RNA species among which miRNAs are the most abundant type). This
physiological communication channel between different cell types is known to be altered
in pathological conditions [135]. In this regard, EVs secreted from reactive microglia were
shown to be enriched in specific miRNAs, including miR-146a-5p that can be transferred
to neurons, thereby downregulating neuronal synaptic targets such as synaptotagmin1
(Syt1) and neuroligin1 (Nlg1), negatively affecting dendritic spine density and excitatory
synapses reduction [106]. Of interest, miR-26a, enriched in astrocyte-derived EVs, can be
transferred to hippocampal neurons modulating their dendritic complexity [50].
Therefore, besides regulating synaptic-related proteins and transcription factors im-
plicated in synaptic plasticity, miRNAs targeting genes related to Aβ and tau metabolism
and activity can also contribute to synaptic dysfunction during AD, which may be further
modulated by glial cells during neuroinflammation.
4. miRNAs as Biomarkers of AD
4.1. Current Biomarkers for AD
The increasing incidence of AD project devastating numbers: 152 million people will
be living with dementia by 2050 [136] while the annual cost of dementia will reach 1 trillion
dollars. The massive impact of the disease on the health and economic systems, as well
as on families and caregivers, raises the pressure to accelerate the search for effective
treatments able to, at least, delay the disease progression, but also to validate diagnostic
tools that enable earlier detection of the disease [136]. Since MCI patients converted to AD
at an annual rate of 17.2 percent [137], an earlier diagnosis would allow a better scenario for
potential therapies to succeed, avoiding the limitation of an environment where neuronal
death is already widespread and allowing the inclusion in clinical studies of patients in
early stages of the disease, increasing the possibility of achieving better therapeutic results.
Currently, the use of biomarkers that can identify AD during its asymptomatic
phase [138–140] is limited to Aβ1–42/Tau levels in cerebrospinal fluid (CSF) and imag-
ing techniques such as the positron emission tomography (PET) that allow the observation
of Aβ accumulation in the brain or 18F-fluorodeoxyglucose-PET (FDG-PET) to detect the
decrease in glucose metabolic rate. Even combination of imaging approaches at different
stages of the diagnosis are being evaluated to improve the available diagnostic tools [141].
However, due to their invasiveness and/or cost, they are not able to be included in routine
clinical screenings, needed for early detection. In addition, recent studies discourage the
use of CSF Aβ levels as a tool for detecting MCI cases since the accuracy in these cases is
lower than recommended [142].
A promising candidate for monitoring disease progression and treatment response in
pre-clinical research is the Neurofilament Light Chain (NfL). Remarkably, work done on
the Dominantly Inherited Alzheimer Network (DIAN) demonstrated that the increased
NfL levels in serum and CSF predict disease progression and brain neurodegeneration at
asymptomatic stages of familial AD [143]. Of importance, NfL would constitute a general
marker of neurodegeneration regardless of the subjacent cause [144].
4.2. Synaptic-Related miRNAs as Early Biomarkers for AD
The potential value of other molecules present in biological fluids (including CSF,
blood, urine, and tears) to differentiate between AD and control subjects are also under
evaluation. In this regard, miRNAs, close modulators of the specific pathogenic processes
underlying AD and present in all these circulating fluids, are presented as promising
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candidates. Easily measured by simple and affordable techniques, including quantitative
real-time PCR (RT-qPCR), miRNAs detection would allow a cost-effective and non-invasive
method that could certainly be included in screening studies and patient follow-up over
time.
miRNAs dysregulated either in brain or circulating fluids during AD pathology have
been described over the last years and are the subject of recent review articles [145,146].
Some miRNAs already commented in this review (including miR-26b, miR-34a/c, miR-
125b, miR-146a, and miR-210) have been described to be altered in brain and blood from AD
patients, although the direction of changes is not always consistent between both miRNA
sources [145,146]. Moreover, miRNAs isolated from AD plasma and serum (including
miR-107, miR342-3p, miR-15b-5p, miR-545-3p, and miR-191-5p) have been proposed as
potential AD biomarkers [145]. In addition, miR-455-3p, related to Aβ toxicity modulation,
has been proposed as potential AD biomarker since increased levels observed in serum
are consistent with levels in AD brains, fibroblasts, lymphocytes, and even AD transgenic
models. Furthermore, a panel of miRNAs involved in pathological processes underlying
AD, such as neuroinflammation, has been proposed as a diagnostic tool to predict AD
onset, since the ability of a single miRNA to detect prodromal AD has not been fully
demonstrated [146].
While intensive research is being done on miRNA-based biomarkers for AD, the
relationship between synaptic function regulation and AD biomarkers is not present in
many studies in the field. Most relevant findings in synaptic-related miRNAs obtained
from circulating biofluids of MCI and AD patients and their potential value as biomarkers
are summarized in Table 2, where it is evident that most studies have been done in blood
samples, including serum and plasma, indicating an interest to explore less invasive
biomarkers.
Table 2. Synaptic-related miRNAs suggested as mild cognitive impairment (MCI)-Alzheimer’s disease (AD) biomarkers.













HCC = 10 + 18 CSF Aβ
[147]AD = 10 + 18 ↑ N/A N/A CSF tau
Serum
HCC = 7
MMSE [148]MCI = 7
AD = 7 ↓ N/A N/A
# miR-23a Serum
HCC = 15 + 30 PD and
VD/No MMSE
[149]AD = 15 + 30 ↑ 0.71 57/83
# miR-26a Serum
HCC = 9 + 86











MMSE [152]AD = 22 0.82 N/A CSF tau
Blood
HCC = 22
MMSE [153]AD = 48 ↑ 0.81 N/A
# miR-29a
Serum
HCC = 15 + 30
MMSE [149]AD = 15 + 30 ↑ 0.71 43/97
Serum
HCC = 7
MMSE [148]MCI = 7
AD = 7 ↓ N/A N/A
CSF
HCC = 10 CSF Aβ
MMSE [154]AD = 10 ↑ N/A N/A CSF tau
CSF
HCC = 20
MMSE [155]AD = 18 ↑ N/A N/A
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MMSE [151]AD = 48 ↑ 0.83 93/- CSF tau
Serum
HCC = 7
MMSE [148]MCI = 7
AD = 7 ↓ N/A N/A
CSF
HCC = 10 CSF Aβ
MMSE [154]AD = 10 ↑ N/A N/A CSF tau
# miR-34a
Plasma
HCC = 21 + 15
PD/Yes
CSF Aβ
MMSEGDS [156]MCI = 21 + 15 CSF tau
AD = 21 + 15 ↓ 0.79 80/71 ApoE 4
Plasma
HCC = 27
MMSE [94]AD = 25 ↑ 0.81 84/74
CSF and
plasma
HCC = 10 CSF Aβ
MMSE [154]AD = 10 ↓ N/A N/A CSF tau
miR-34c Plasma
HCC = 27





MMSE [151]AD = 48 ↓ 0.8 N/A CSF tau
miR-107 Plasma
HCC = 120






MMSE [151]AD = 48 ↑ 0–84 74/82 CSF tau
CSF
HCC = 20





MMSE [158]AD = 105 ↑ 0.85 80/68
# Serum
HCC = 15 + 30





MMSE [152]AD = 22 0.82 N/A CSF tau
CSF
HCC = 10 CSF Aβ
MMSE [154]AD = 10 ↓ N/A N/A CSF tau
miR-128 Plasma
HCC = 50









MMSE [160]AD-MCI = 16
AD = 16 ↓ 0.77 N/A
Serum
HCC = 44 CSF Aβ
MMSE [151]AD = 48 ↓ 0.79 N/A CSF tau
Serum
HCC = 76
[161]MCI = 66 ↓ 0.91 70/100
miR-134 Plasma
HCC = 50











MMSE [151]AD = 48 ↓ 0.87 N/A CSF tau
Blood







pMCI = 19 ↑ N/A N/A
CSF and
plasma
HCC = 10 CSF Aβ
MMSE [154]AD = 10 ↓ N/A N/A CSF tau
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HCC = 9 + 86
MMSE [150]AD = 19 + 121 ↓ 0.78 72/73
Serum
HCC = 155
MMSE [158]AD = 105 ↑ 0.74 75/64
Plasma




[163]MCI = 26 0.84 85/86
AD = 56 0.77 70/86
Serum
HCC = 7
MMSE [148]MCI = 7
AD = 7 ↓ N/A N/A
# miR-191 Plasma
HCC = 20 + 17
[164]MCI = 9
AD = 11 + 20 0.95 95/76
# miR-206 Serum




AD = 25 ↑ N/A N/A
MMSE [165]
# miR-210 Plasma




[163]MCI = 26 0.74 77/71








MMSE [167]AD = 89 ↑ 0.93 84/97
miR-501 Serum
HCC = 22 ApoE MMSE [168]AD = 36 ↓ 0.82 53/100
miRNAs also included in a molecular signature in Table 3 are indicated (#). Source of miRNAs, Evs: Extracellular vesicles. Discovery
cohorts and validation cohorts (D + V) are shown when reported. Control subject are referred in all cases as HCC: Healthy cognitive
controls. MCI: Mild cognitive impairment. AD: Alzheimer’s disease. sMCI: Stable MCI. pMCI: Progressor MCI. Sense of change in miRNAs
levels are shown as arrows for increased levels ↑ and decreased levels ↓. AUC: Area under the curve, sensitivity and specificity values
are included when available. If AUC available, values over 0.7 were considered for inclusion. If more than one diseased cohort, several
AUC values are included and are shown in the same line corresponding to the group being compared to HCC. Other neurodegenerative
diseases (NDD) tested in the same study are reported: PD: Parkinson’s disease, VD: Vascular dementia, FTD: Frontotemporal dementia
DLB: Dementia with Lewy bodies. Specificity of miRNA changes for detecting MCI and/or AD subjects is indicated with YES; when
miRNA changes are also present in other NDD, No is indicated. Cognitive tests used for patients’ inclusion in each cohort are indicated as
MMSE: Mini-Mental State Examination and GDS: Geriatric Depression Scale.
For instance, miR-132 decrease in serum from MCI and AD patients [151,161] has
been reproduced in plasma samples [160], however an increase has also been reported in
MCI subjects by Sheinerman and colleagues [159], evidencing that reproducibility between
studies can be difficult even when obtaining miRNAs from the same sample source. In the
same study, they have also reported the increase of another member of the same family,
miR-134, and remarkably, both miRNAs showed notable performance with an area under
the curve (AUC) over 0.9 (close to the ideal value of 1, which represents the maximum
accuracy of a classifier distinguishing between two groups [169] and sensitivity between
82% and 86% for detection of MCI cases. Interestingly, miR-132 has also been proposed as
a member of a serum-based signature for MCI detection, together with miR-206, which is
also downregulated in MCI serum [161]. With an outstanding AUC of 0.98, a sensitivity
of 85%, and specificity of 98%, this synaptic-related miRNA signature seems certainly
promising.
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Table 3. miRNA-based signatures including at least one synaptic-related miRNAs proposed as MCI-AD biomarker.

















































HCC = 38 + 44
MCI = 17
AD = 23 + 19 0.83
CSF Aβ
CSF tau MMSE [172]
miR26b, miR125b CSF HCC = 18AD = 22 0.80
CSF Aβ
CSF tau MMSE [152]
miR-191, miR-15b Plasma
HCC = 20 + 17
MCI = 9























Serum HCC = 9 + 86AD = 19 + 121 0.99 93/99
MMSE
CDR [150]
Synaptic-related miRNAs within each signature are highlighted in bold letters. Discovery cohorts and validation cohorts (D + V) are
shown when reported. Control subject are referred in all cases as HCC: Healthy cognitive controls. MCI: Mild cognitive impairment. AD:
Alzheimer’s disease. AUC: Area under the curve, sensitivity and specificity values for the combination of miRNAs in the signature are
included when available. If more than one diseased cohort, several AUC values are included and are shown in the same line corresponding
to the group being compared to HCC. Other neurodegenerative diseases (NDD) tested in the same study are reported: PD: Parkinson’s
disease, MS: Multiple sclerosis, FTD: Frontotemporal dementia. Specificity of miRNA changes for detecting MCI and/or AD subjects is
indicated with YES; when miRNA changes are also present in other tested NDD, No is indicated. Cognitive tests used for patients’ inclusion
in each cohort are indicated as MMSE: Mini-Mental State Examination and GDS: Geriatric Depression Scale. CDR: Clinical dementia rating.
The use of miRNA-based signatures, which consider the alteration of more than one
miRNA at the same time, can give higher accuracy, sensitivity, and specificity values that
could be an advantage for potential diagnostic tools as exposed in Table 3.
In this regard, another signature based in four serum-miRNA levels, including
synaptic-related miR-29a, miR-125b, and miR-23a has shown an encouraging performance
for differentiating AD cases from healthy cognitive controls (HCC) [149]. The diagnostic
value of miR-29a/b family has been tested both in serum and CSF [148,149,151,154,155]
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although results are not consistent between studies, the alteration of these miRNAs in
biological fluids during AD pathology seems to be clear. On the other hand, miR-125b and
miR-23a increase has been consistently observed in serum [149,158], displaying good capac-
ity of differentiation between AD and control subjects specifically for miR-125b alone. The
potential of miR-125b has also been tested in CSF [152,154], where it has been proposed as
a specific tool since, in addition, it is able to distinguish AD from FTD patients [152]. An in-
crease in related miR-125a levels has also been described in CSF from AD patients [151,155],
constituting a potential biomarker as previously reported, with special value differentiating
also AD from FTD patients [151].
Altered levels of miR-34a were observed both in plasma and CSF [94,154,156], and
values near 0.8 were reported for the AUC for plasma-based miRNA performance as AD
biomarker. Another member of miR-34 family, miR-34c, was reported to be increased
in plasma samples from AD patients, and more interestingly, in mild AD patients [94].
Furthermore, both family members have been included in a signature combining miRNA
and piRNAs (PIWI-interacting RNAs) that can distinguish AD cases with 83% accuracy.
Although the great value of this signature is predicting the conversion of MCI to AD, this
capacity is due to piRNAs levels [172].
Regarding longitudinal studies, to our knowledge, only a few articles have evaluated
miRNA levels over time as a predictive tool of MCI progression to AD. Indeed, miR-206
(mentioned above for its potential to distinguish MCI patients) has also shown a good
prognostic capacity to classify MCI progression to AD over five years [165]. In another
study, miR-181a and miR-146a levels in blood from MCI patients have been documented
as a useful tool to distinguish between MCI patients that progress to AD (pMCI) and
those who remain stable in MCI state (sMCI) two years after the first measure [162]. The
levels in serum of another member of the family, miR-181c, have also been reported to
distinguish MCI and AD from control subjects, although the direction of level changes
is inconsistent between studies [148,150,158]. Interestingly, an increase in miR-181c in
plasma samples from MCI and AD patients has been reported to be specific compared
with an FTD cohort [163]. Moreover, both miR-181a and miR-181c have been included in
individual plasma-based miRNA signatures. The first one, composed of six miRNAs [170],
also include miR-9, which levels have been reported to similarly be altered in whole-
blood [173], serum [148], and exosome-enriched CSF [147] from AD patients compared to
HCC. With a high AUC, sensitivity, and specificity, this signature can differentiate AD, PD,
and FTD from HCC, constituting a useful tool for detecting general neurodegeneration.
Interestingly, the signature including miR-181c, is composed of two other synaptic-related
miRNAs: miR-92a-3p and miR-210-3p, and besides the potential for distinguishing MCI
and AD patients from HCC, promising preliminary results were reported in the signature
capacity for evaluating MCI progression to AD after a follow-up of the patients from 1 to
11 years [163]. The potential value of miR-92a as biomarker for AD has also been evaluated
in serum, where its levels were shown to be decreased during AD pathology [151].
miR-26b consistent upregulation has been reported in serum and whole blood sam-
ples from AD patients [152,153,174], whereas downregulation of miR-26a [150] has been
reported in a study that comprised one of the biggest cohorts of AD patients included in
this review. While miR-26b levels in CSF samples exhibited specificity for AD detection
with an AUC value of 0.82 and the capacity to distinguish AD from FTD patients [152];
differentiation between AD and FTD patients was not possible in serum despite a higher
AUC (0.97) for AD cohort [151]. Interestingly, both members of the family were comprised
in a blood-based miRNA signature with other 10 miRNAs [171] including miR-107, also
proposed itself as plasma biomarker for MCI and AD detection. Remarkably, this signature
was tested in other neurodegenerative diseases, such as MS and PD, exhibiting specificity
for MCI and AD detection. Furthermore, while miR-26b was also included in a CSF-based
signature together with miR-125b [152]; miR-26a was included in serum-based miRNA
signature together with miR-181c and other four miRNAs. This last signature’s AUC,
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sensitivity, and specificity is the highest included in this review for detecting AD cases,
with 0.99 accuracy, 93% sensitivity and 99% specificity [150].
miR-137 and miR-501, both known to target GRIA1, have been proposed as potential
AD biomarkers after decreased levels identification in serum [148,168], while miR-128 [159]
and miR-191 [164] have been proposed as plasma-based biomarkers for AD with an
AUC performance over 0.95. miR-191 has been considered together with miR-15 for
diagnostic value improvement, and slightly better results were achieved, especially for
specificity [164].
Consistent downregulation of miR-146a levels was reported in serum, plasma, and
CSF from AD patients [151,154]. Despite the small cohort size, downregulation of miR-451
was also observed in plasma EVs with high AUC value distinguishing AD cases from HCC
and specific results compared to Dementia with Lewy bodies (DLB) plasma samples [166].
Increased levels of miR-485-3p were reported in AD serum compared to healthy controls,
with an AUC value of 0.93 differentiating both groups [167].
4.3. Potential and Limitations of Synaptic-Related miRNAs as Early AD Biomarkers
As mentioned above, miRNAs could also be isolated from exosome-enriched or EVs
fraction, though the best source for obtaining miRNAs-enriched samples is still unclear.
Some studies propose that exosome-related miRNAs could represent a stable source of miR-
NAs over time and differentially expressed during pathological states [175,176], whereas
other reports suggest that miRNAs expression within exosomes could be certainly low [177].
Even miRNAs included in vesicles and whole plasma cell-free miRNA profiles have been
reported to be different [178]. The possibility of diverse miRNA sources, including CSF,
plasma, and serum, is an advantage but also raises a problem when looking for repro-
ducibility between studies. However, limitation goes beyond the above mentioned, since
reported changes are often inconsistent within the same sample type, as observable in
Table 2. The cohort size the parameters used for groups classification, subjects’ inclusion–
exclusion criteria, miRNAs extraction and quantification methods, and statistical analysis
performed, could make intricate the comparison between studies. Moreover, although
the ROC curve analysis is not the only method available for testing diagnostic value, it
is certainly the most used. However, the information given in some studies is limited to
the significant or not significant differential expression between groups, which beyond the
importance of this information; it does not determine the diagnostic value of a molecule
itself.
The advantages and potential value of miRNAs as early biomarkers for AD highlight
the urgent need for protocols standardization as an essential tool that would allow a faster
progress in obtaining more reliable results in order to bring the advances to the clinics.
Remarkably, molecular diagnostics companies, such as DiamiR, are already developing
and commercializing miRNA-based technologies, constituting a reflection of the progress
made in the area and the real possibilities of incorporating miRNAs as biomarkers for AD
not only in screening and diagnosis but also as a valuable tool for improving definition of
clinical trials participants.
5. miRNAs as Therapeutic Targets
In addition to the potential of miRNAs as biomarkers for AD, their capacity to regulate
several targets related to the pathology suggest that they may be also considered as thera-
peutic targets. miRNAs can be modulated pharmacologically by administration of specific
compounds (such as anti-inflammatory drugs) or by using antisense oligonucleotides or
double-stranded synthetic oligonucleotide miRNAs that inhibit or mimic endogenous
miRNAs function, respectively. Recent studies using in vitro approaches and AD animal
models have shown that regulation of specific miRNAs may impact on neuroprotection,
cognitive function, and neuronal regeneration (reviewed in [179]). Interestingly, some
synaptic-related miRNAs discussed above, including miR-30a, miR-124, miR-128, and
miR-146a, which regulate targets related to Aβ accumulation and synaptic dysfunction,
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have been suggested as potential therapeutic targets for AD [179]. In addition, miR-485, re-
lated to neurotransmitter release [86] and neuroinflammation [167], has also been proposed
both as potential AD biomarker and therapeutic target [167]. Furthermore, multitargeted
therapeutic strategies such as the combination of acetylcholinesterase (AChE) inhibitors
and modulation of specific miRNAs are also under evaluation [180].
Two key limitations of approaching miRNAs as therapeutic targets are 1) their capacity
to regulate several transcripts (up to hundreds of them) simultaneously, and 2) the difficulty
to achieve efficient miRNA delivery. Regarding the latter, a recent study using engineered
exosomes to deliver miR-29 in a rat model of induced Aβ pathology, showed a rescue of
memory deficits [181].
6. Concluding Remarks
Substantial progress has been made in the study of miRNAs as biomarkers of AD,
which is especially important in finding miRNAs capable of detecting asymptomatic stages
of the disease. In this review, we highlighted the huge potential of synaptic-related miRNAs
in this regard; nonetheless, much remains to be explored. For instance, the potential of
miRNAs for predicting MCI conversion into AD dementia has only been explored in a
few studies. Therefore, it is necessary to widely perform longitudinal studies in future
research. Screening of pre-existing blood banks could be a valuable source of material
for studies that aim to elucidate the alteration of specific miRNAs during the pathology
progression. This kind of studies would allow the acquisition of an immense amount of
data on the evolution of specific miRNAs levels over the years in healthy controls and MCI
and AD patients, which would allow not only to confirm the significance of miRNAs in
AD diagnosis but also to probe their potential as a valuable prognostic tool.
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